Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?

Valerie J. Kinchen, Andrea L. Cox, Justin R. Bailey

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


While licensed vaccines elicit protective antibody responses against a variety of viral infections, an effective vaccine for hepatitis C virus (HCV) has remained elusive. The extraordinary genetic diversity of HCV and the ability of the virus to evade the immune response have hindered vaccine development efforts. However, recent studies have greatly expanded the number of well characterized broadly neutralizing human monoclonal antibodies (bNAbs) against HCV. These bNAbs target relatively conserved HCV epitopes, prevent HCV infection in animal models, and are associated with spontaneous clearance of human HCV infection. In this review, recent high-resolution bNAb epitope mapping and structural analysis of bNAb–epitope complexes that may serve as a guide for vaccine development are discussed along with major obstacles.

Original languageEnglish (US)
Pages (from-to)854-864
Number of pages11
JournalTrends in Microbiology
Issue number10
StatePublished - Oct 2018


  • HCV vaccine
  • broadly neutralizing antibodies
  • hepatitis C virus

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology


Dive into the research topics of 'Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine?'. Together they form a unique fingerprint.

Cite this